Navigation Links
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Date:4/24/2009

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes

HAYWARD, Calif., April 24 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of patient accrual to a phase 1b clinical study evaluating ITCA 650 (DUROS(R) continuous delivery of exenatide). The study is being conducted at multiple centers in the United States and involves the treatment of 44 patients with type 2 diabetes for a period of 4 weeks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Intarcia began the development of ITCA 650 in 2007 after acquiring an exclusive worldwide license to the DUROS delivery technology. The DUROS delivery technology consists of the DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

Intarcia's phase 1 study is evaluating the safety and pharmacokinetics of ITCA 650 at several doses over a treatment period of 4 weeks. ITCA 650 therapy is administered for the full course of therapy with a single insertion of the DUROS device on day 1 and removal on day 29. Results of the phase 1 study will support selection of doses to be evaluated in a controlled phase 2 study planned for later in 2009 in which longer durations of treatment with a single ITCA 650 insertion will be evaluated. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. The goals of the ITCA 650 program are to enha
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... India, July 5th, 2007 – Several data,presentations ... be presented at ,International Brain Research ... be held at Melbourne, Australia during,July 12-17, ... will be presenting new,data for 4 promising ...
... STANFORD, Calif.--(BUSINESS WIRE)--Jul 5, 2007 - Scientists' hunt,for ... suspects and,found so many treatments with different mechanisms ... the Stanford,University School of Medicine have identified one ... causes and treatments,for depression converge., They found that ...
Cached Medicine Technology:Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience 2Stanford Researchers Find Brain Pathway of Depression in Rats 2Stanford Researchers Find Brain Pathway of Depression in Rats 3Stanford Researchers Find Brain Pathway of Depression in Rats 4
(Date:5/21/2013)... New York (PRWEB) May 21, 2013 ... surgery robot lawsuit is nearing its conclusion in ... to Bloomberg.com, during closing statements yesterday, an attorney for ... alleging the company wanted to tie sales and services ... all the training to keep control of surgeons, to ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... Two executives from human resources and ... which strategies can be most effective to better manage ... members who are taking them, in an upcoming May ... to Manage Specialty Drugs to Reduce Costs and Ensure ... main driver for rising prescription drug costs, which are ...
(Date:5/21/2013)... May 21, 2013 While North Carolina ... with comprehensive travel guides. Brunswick Plantation & Golf Resort ... that include access to 27 holes of "Top10" championship ... in North Carolina, knowing the Top 10 ... takes away the overwhelming task of selecting the course ...
(Date:5/21/2013)... Octo Consulting Group, an award-winning ... solutions to the Federal marketplace, has named Tracy ... the newly created role, Denny will be responsible ... firm’s business development function to include business development ... leading strategies to achieve the firm’s strategic growth ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... News) -- Women who suffer recurrent miscarriages have a greatly ... new study. Researchers analyzed data from more than 11,500 ... that 25 percent had experienced at least one detectable miscarriage, ... percent had experienced a stillbirth. Over a follow-up of ...
... MAResearchers at Harvard-affiliated McLean Hospital and the University of ... autism to date. The test was able to detect ... percent accuracy. The study will be published online the ... The test, which uses MRI to measure deviations in ...
... -- Crohn,s disease may cause post-traumatic stress disorder (PTSD), ... 600 Swiss adults with Crohn,s disease, an incurable inflammatory ... The study participants underwent PTSD assessment at the start ... found to have the disorder. All the participants were ...
... at deaths from any cause found that a body mass ... lowest risk of death in healthy non-smoking adults. Investigators also ... people who are overweight and obese. Previous studies that examined ... only modestly increased risks of death and others showing a ...
... 2010) During the decade since the advent of ... people living with HIV/AIDS (PLWHA) sharply decreased in the ... deaths attributable to AIDS-defining illnesses, just as there was ... to heart, kidney, and liver disease. These data from ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- The case of ... colitis -- and actually got better -- sheds light on ... study suggests. "Our findings in this case report suggest ... roundworm can alleviate the symptoms of ulcerative colitis," said ...
Cached Medicine News:Health News:Miscarriages May Raise Heart Attack Risk 2Health News:University of Utah and Harvard researchers take major step toward first biological test for autism 2Health News:Study Suggests Link Between Crohn's Disease and PTSD 2Health News:NIH study identifies ideal body mass index 2Health News:NIH study identifies ideal body mass index 3Health News:Worm Therapy Shows Promise for Ulcerative Colitis 2Health News:Worm Therapy Shows Promise for Ulcerative Colitis 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: